ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
39,100
-300 (-0.76%)
Feb 21, 2025, 3:30 PM KST
87.53%
Market Cap 1.89T
Revenue (ttm) 32.32B
Net Income (ttm) -49.04B
Shares Out 48.28M
EPS (ttm) -1,022.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,366,180
Average Volume 1,933,069
Open 39,100
Previous Close 39,400
Day's Range 38,650 - 40,200
52-Week Range 21,200 - 47,250
Beta 0.90
RSI 54.41
Earnings Date Mar 12, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.